Summary
- Novavax is the hypercoaster of stocks having crested $300 in 02/2022, falling to <$130 several months on and then doubling and then crashing.
- Novavax has big plans to reclaim its former heights on the back of its highly differentiated and now widely approved COVID vaccine.
- Despite its impressive vaccine, Novavax has proven to be a treacherous investment.
Novavax (NASDAQ:NVAX) has been on the brink of greatness several times over its long decades as a public company. It has always fallen short when it came to generating revenue. The pandemic has changed things for Novavax. As matters now stand. The Novavax story has become much more interesting.
I submit that it remains treacherous. Trading at ~$18.50 as I write on 09/29/2022, I rate it a hold.
Novavax rose from the dead like a mighty Phoenix and then flopped
On 05/08/2019 Novavax announced its imminent one-for-twenty reverse stock split:
…to increase the per share trading price of the Novavax’ common stock to enable Novavax to satisfy the minimum price requirement for continued listing on the Nasdaq Global Select Market
At the time it was trading <$0.40. Its reverse split bumped its shares up to $6.40 where they traded when the market opened following the split. It then meandered <$10 until late 02/2020 as the pandemic started to take hold and it bruited a vaccine to combat it.
